It is always interesting when, just before I write up a quarterly report appraisal on a specific company, I use the search functionality on the site and take a look at what I wrote the previous quarter. In the case of the agricultural company Syngenta, my first observation is that the share price is almost unchanged from three months ago at just under US$80 (to quote the US Dollar issue).
After the H1 numbers, I talked about the structural/thematic opportunity in agriculture due not only to rising demand from the emerging markets but also phenomenal pricing power shown in the sector. This was also apparent when I reviewed the higher valued sector peer Monsanto the other week (link here).
The first good news I noted is that the pricing power continues in Q3 (3% as shown below) and volume increases were higher too. That's a good start.
With around 40% of the sales in Latam, growth here driven by the record Brazilian soybean acreage is helping to drive these numbers. Generally though, as shown below, sales growth is occurring around the world.
With both crop protection and seeds showing strong individual growth, the numbers look suitably balanced and inherently strong.
So what is there to worry about? This comment by the CEO in the document released by the company is informative:
'The third quarter performance demonstrates our ability to sustain growth across our business in a context of crop price and currency volatility'.
Ah...back to currency volatility. The challenge for Syngenta is that - as mentioned above - much of its sales (and hence profit) momentum is in Latam, specifically Brazil...and the Brazilian Real has been weak. Now the numbers released today were just sales numbers but combining the pricing power noted above with continued sales growth, the company said the following about the earnings outlook:
'Full year earnings will also reflect a lower than expected currency benefit. Final results will depend on the progress of the Latin American season but at this stage earnings per share are expected to be close to last year's underlying level'.
This should not be particularly new news to the market as this was the guidance at the H1 stage.
And then looking medium-term:
'we remain on track to deliver our target of $25 billion in sales of our eight key crops in 2020. We expect improved profitability in 2014'
US$25bn in sales is a CAGR of 8% from here. There are not many companies around who give that sort of prediction. Additionally I think that Syngenta's relative optimism also comes from continued good agricultural economics for the sector:
Three months ago I talked about around 20% upside to the Syngenta share price if I put it on a growth rating of x12 EV/ebit. I stick with that view today. From here that would take the stock back to the highs of the last year (or around US$95 in the US).
Within an opportunistic agricultural theme (see link here), Syngenta remains a core holding.




No comments:
Post a Comment